1380427-65-5

Upstream product

• 1380429-75-3 1-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethanol 
• 1380429-74-2 1-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethanone 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 
• 224776-34-5 5-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-thioxo-2,3-dihydro-4(1H)-pyrimidinone 
• 1380429-76-4 1-chloro-4-{[4-(1-chloroethyl)phenyl]oxy}-2-(trifluoromethyl)benzene 
• 224776-32-3 methyl 3-(1-methyl-1H-pyrazol-4-yl)propanoate 
• 1295583-21-9 methyl (2E)-3-(1-methyl-1H-pyrazol-4-yl)prop-2-enoate 
• 689251-97-6 (E)-3-(1-methyl-1H-pyrazol-4-yl)acrylic acid 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 6294-93-5 4-chloro-3-trifluoromethylphenol 

Relevant academic research and scientific papers

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).